Guest guest Posted June 17, 2004 Report Share Posted June 17, 2004 Knowledge of the targets of the T cell response to prostate cancer is of considerable utility in the development of more highly specific approaches to immunotherapy via specific immunization. In addition, it can allow the production of reagents for the detection and quantification of immune responses in cancer patients. snip This work represents the first identification of a T cell defined epitope from mouse prostate cancer cells, and raises the possibility that the human homologue might be useful in the immunotherapy of human prostate cancer. Additionally, our approach offers the possibility of beginning the development of tumor immunotherapy with targets that are already validated immunologically. This approach, first developed in the laboratory, will be undertaken in the context of combination therapy (CTLA blockade combined with antigen presentation) in prostate cancer patients. In particular, we will evaluate the safety, efficacy, and immunologic effects of GM-CSF therapy combined with CTLA-4 blockade. http://cc.ucsf.edu/prostate_spore/prjct_es-ja.html Kathy Meadehttp://www.vapcacoalition.org/ Arlington Educational Consulting phone fax It is not the strongest of species that survive, nor the most intelligent, but the ones most responsive to change. -- Darwin Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.